APA (7th ed.) Citation

I, F., Y, K., A, M., T, C., A, P., H, S., . . . E, R. (2025). BRAF inhibitor or BRAF/MEK inhibitor treatment for patients with metastatic BRAF V600E mutated differentiated thyroid cancer. Archives of endocrinology and metabolism, 69(6), e250127. https://doi.org/10.20945/2359-4292-2025-0127

Chicago Style (17th ed.) Citation

I, Finkel, et al. "BRAF Inhibitor or BRAF/MEK Inhibitor Treatment for Patients with Metastatic BRAF V600E Mutated Differentiated Thyroid Cancer." Archives of Endocrinology and Metabolism 69, no. 6 (2025): e250127. https://doi.org/10.20945/2359-4292-2025-0127.

MLA (9th ed.) Citation

I, Finkel, et al. "BRAF Inhibitor or BRAF/MEK Inhibitor Treatment for Patients with Metastatic BRAF V600E Mutated Differentiated Thyroid Cancer." Archives of Endocrinology and Metabolism, vol. 69, no. 6, 2025, p. e250127, https://doi.org/10.20945/2359-4292-2025-0127.